Bo Barnhart

Bo is Vice President of Translational Research at AbCellera. He brings his expertise to help partners evaluate, optimize and nominate developable lead candidates from the large panels of high-quality antibodies generated by AbCellera. Bo has over 12 years of antibody drug development experience in the pharmaceutical industry. Before joining AbCellera, he was a Senior Director at Bristol-Myers Squibb, where he progressed more than ten therapeutics, spanning target identification up to early clinical development, with several entering first-in-human testing. Bo’s experience in leading antibody programs also includes antibody engineering and developability evaluation as well as building and testing translational hypotheses. Prior to entering industry, he was a postdoctoral fellow at the University of Pennsylvania. He completed his PhD in Immunology at the University of Chicago and his BA in Biology and English Literature at Rutgers University.

Tryn Stimart

Tryn has over 16 years experience in biotech and pharma spanning M&A and financing, FDA regulatory procedures, licensing, commercial and patent litigation, IP strategy and prosecution, and due diligence. Before joining AbCellera, he was a partner at Gibbons P.C. in Manhattan, NY. In private practice, Tryn represented a variety of biotech and pharma clients including Gilead, Takeda, Gevo, Sunovion, Syngenta and Adare Pharma.  Tryn also served as an Advisor to the Advanced Technology Program of the U.S. Department of Commerce. He is also a former United States Naval Officer (Lieutenant Commander) with 10 years of service in active and reserve forces.Tryn has a JD from American University Washington College of Law (cum laude) and was a senior editor on Law Review, an MSc in Chemistry from Old Dominion University, and BScs in Biochemistry and Genetics & Cell Biology from the University of Minnesota.

Véronique Lecault

Véronique Lecault is Co-founder, Chief Operating Officer and member of the Board of Directors at AbCellera. She received her PhD in Chemical and Biological Engineering from the University of British Columbia, where she co-invented the high-throughput microfluidic platform that is now part of AbCellera’s core technology. A strong advocate of entrepreneurship, science and technology, Véronique was recently recognized as a STEM Star Influencer by BCBusiness and as one of Canada’s Top 40 Under 40. She holds a B.A.Sc. in Chemical Engineering/Honours B.Sc. Biochemistry (Biotechnology) dual degree from the University of Ottawa and is a recipient of the L’Oreal-UNESCO For Women in Science Mentorship Award.

Sherie Duncan

Sherie is Vice President of Research Partnerships at AbCellera. She has successfully managed over 25 discovery programs to completion. Sherie has over 20 years of management experience in biotechnology, science outreach and other industries, and is an expert in immunology, cell biology, and single cell assays. She has been awarded several scholarships from the Natural Sciences and Engineering Research Council of Canada (NSERC) as well as the British Columbia Industrial Innovation Scholarship. Sherie has a PhD in Experimental Medicine from the University of British Columbia and a BSc in Biological Sciences from Simon Fraser University.

Kathleen Lisaingo

Kathleen is a Co-founder and Vice President of Discovery at AbCellera. A co-inventor on several patents, Kathleen has been instrumental in developing custom single-cell assays and dramatically increasing the throughput of AbCellera’s core screening technology. An expert in cell biology and high-throughput screening, she has led the growth of the Discovery teams at AbCellera. Kathleen has a PhD in Experimental Medicine at the BC Cancer Research Centre and a BSc (Hons) in Biophysics from the University of British Columbia.

Carl Hansen

Carl Hansen is AbCellera’s founding CEO. Until August 2019, Carl was a Professor at the University of British Columbia, where he co-authored over 65 manuscripts in the fields of microfluidics, immunology, genomics, and nanotechnology. He is an inventor of over 50 US patents and 63 US patent applications that are represented in 7 commercial products. He received the Michael Smith Career investigator award and was recently named one of the “Top 5 Canadian CEOs who elevate their companies.” Carl received his PhD in Applied Physics/Biotechnology from Caltech, and a BASc in Engineering Physics and Honors Mathematics from the University of British Columbia. Before leading AbCellera, he was a scientific Co-Founder of Precision Nanosystems, a Vancouver-based company developing next-generation delivery technology for genetic medicines, and served on the SAB of Fluidigm Corp.

Murray McCutcheon

Murray is responsible for negotiating AbCellera’s research, partnership, and license agreements and is a key contributor to the development and execution of corporate strategy.  He has over 12 years of experience in technology commercialization and early-stage venture development. Before joining AbCellera, Murray was a Business Development Manager at Harvard University’s Office of Technology Development.  Prior to Harvard, he was a Senior Consultant at Lux Research in Boston, where he specialized in technology strategy, market and competitive analysis, and M&A and investor diligence. Murray completed a postdoctoral fellowship at Harvard’s School of Engineering and Applied Sciences, and has PhD, MSc, and BSc degrees in Physics from the University of British Columbia.  He also earned a BA in Philosophy, Politics and Economics from Oxford University, where he studied as a Rhodes Scholar.

Andrew Booth

Andrew became AbCellera’s CFO in 2019 after spending nearly 4 years on the company’s Board of Directors. Prior to joining AbCellera, Andrew spent 10 years at STEMCELL Technologies where he held roles as the CFO and the Chief Commercial Officer. Before STEMCELL, Andrew spent 7 years at General Electric, ending by leading M&A/Business Development for GE Healthcare’s Europe, Middle East, and Africa business and GE Healthcare’s global Life Sciences business based in London. Andrew is Chairman for Precision Nanosystems and a Director at the National Board of Canadian Manufacturers and Exporters. He is also a former Director at the BC Tech Association, at Life Sciences BC and at Light Integra Inc. Andrew holds an MBA from INSEAD and a BASc in Engineering Physics from the University of British Columbia.